Dear Editor, we have read with great interest the Letter to the Editor by Cordova et al. “Why are osteopoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral care?”. We strongly agree with the Authors claiming for “differentiated guidelines for osteoporosis and oncology patients” regarding their risk of Antiresorptive-Related Osteonecrosis of the the Jaw (ARONJ), that is the main form of what is recently known as Medication-Related Osteonecrosis of the Jaw (MRONJ).
Campisi, G., Mauceri, R., Coppini, M., Bedogni, A., Bertoldo, F., Fusco, V. (2024). Author Response to Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”. OSTEOPOROSIS INTERNATIONAL [10.1007/s00198-024-07192-4].
Author Response to Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”
Campisi, Giuseppina
;Mauceri, Rodolfo;Coppini, Martina;
2024-08-16
Abstract
Dear Editor, we have read with great interest the Letter to the Editor by Cordova et al. “Why are osteopoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral care?”. We strongly agree with the Authors claiming for “differentiated guidelines for osteoporosis and oncology patients” regarding their risk of Antiresorptive-Related Osteonecrosis of the the Jaw (ARONJ), that is the main form of what is recently known as Medication-Related Osteonecrosis of the Jaw (MRONJ).
| File | Dimensione | Formato | |
|---|---|---|---|
|
letter to editor-osteoporosis international.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
377.24 kB
Formato
Adobe PDF
|
377.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
